Back to search results

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

Abroad (travel likely)RecruitingPHASE1

Conditions

HIV

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States

    Contact: Study coordinator (Emily Schaeffer) · emily.schaeffer@sfdph.org · 628-217-7456

  • Ponce de Leon Center CRS, Atlanta, Georgia, United States

    Contact: Study coordinator (Ericka Patrick, RN, MSN) · erpatri@emory.edu · 404-616-6313

  • The Hope Clinic of the Emory Vaccine Research Center; Emory University, Decatur, Georgia, United States

    Contact: Study coordinator (Emily Osbourne) · emily.claire.osborne@emory.edu · 404-712-1370

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States

    Contact: Study coordinator (Jose Licona) · jlicona@partners.org · 617-525-9433

  • Columbia Physicians & Surgeons, New York, New York, United States

    Contact: Study coordinator (Anyelina Cantos) · ac4314@cumc.columbia.edu · 212-305-2201

  • NY Blood Center CRS, New York, New York, United States

View source on ClinicalTrials.gov(opens in a new tab)